How does Stryker make money?

STRYKER CORP – Business Breakdown

The Essentials

Stryker Corp is a global medical technology company operating in the Healthcare sector, with a business model anchored in two reportable segments: MedSurg and Neurotechnology and Orthopaedics. The company sells products in approximately 75 countries through a diversified commercial footprint spanning company-owned subsidiaries, branches, third-party dealers, and distributors. Its profile reflects a scaled, diversified medtech platform with meaningful exposure to hospital-based procedures, surgical workflows, and implantable technologies.

In 2025, the business was weighted toward MedSurg and Neurotechnology, which generated $15.647 billion or 62% of net sales, while Orthopaedics contributed $9.469 billion or 38%. The revenue mix suggests a balanced but clearly procedure-driven franchise, with recurring demand tied to clinical utilization, installed base penetration, and product adoption across hospitals and healthcare facilities.

Business Model & Revenue Drivers

Stryker generates economic value through a broad portfolio of medical technologies sold into clinical settings. The company’s revenue base is organized around two primary operating segments:

• MedSurg and Neurotechnology — $15.647 billion in 2025 net sales, representing 62% of total revenue.

  • Medical: $4.204 billion (27%)
  • Endoscopy: $3.807 billion (24%)
  • Instruments: $3.183 billion (20%)
  • Neuro Cranial: $2.485 billion (16%)
  • Vascular: $1.968 billion (13%)

  This segment appears to be the company’s principal growth and scale engine, spanning surgical tools, endoscopic systems, medical devices, vascular technologies, and neuro-related products. The breadth of the portfolio indicates exposure to multiple procedural categories, which can support cross-selling and reduce reliance on any single product line.

• Orthopaedics — $9.469 billion in 2025 net sales, representing 38% of total revenue.

  • Trauma and Extremities: $3.948 billion (42%)
  • Knees: $2.656 billion (28%)
  • Hips: $1.865 billion (20%)
  • Other: $815 million (9%)
  • Spinal Implants: $185 million (2%)

  Orthopaedics remains a substantial revenue contributor, with the mix concentrated in trauma/extremities and large-joint reconstruction. The relatively small spinal implants contribution suggests that this is not the dominant earnings driver within the segment.

Geographically, the company is heavily weighted toward the United States, which accounts for roughly 75–80% of total sales, with International markets contributing approximately 20–25%. This indicates a strong domestic base, while also leaving room for international expansion as a secondary growth lever.

Strategic Edge & Market Positioning

Stryker’s competitive position is supported by both structural and execution-based advantages, but the source material indicates that the more durable edge is rooted in intellectual property and switching costs, particularly in robotics and proprietary technologies.

Economic Moat

• Switching Costs: The strongest structural moat appears in Mako SmartRobotics. The platform has surpassed 1 million Total Knee procedures and 1.5 million total procedures, and includes first-to-market robotic capabilities in revision hip arthroplasty and Mako Shoulder. Surgeons trained on proprietary navigation and robotic workflows face meaningful retraining friction if they switch platforms.
• Patents: Patent protection is explicitly cited as a barrier to duplication of unique designs and processes, including products such as Surpass Elite Flow Diverting Stent and Mako-related expansions. This supports defensibility in product categories where differentiation is technologically intensive.

Execution Advantage

• The company’s MedSurg and Neurotechnology segment posted 16% year-over-year growth, which reflects strong commercial execution, product adoption, and portfolio momentum.
• The breadth of the offering across instruments, endoscopy, medical, vascular, and neuro cranial categories suggests disciplined portfolio management and effective market penetration.
• However, the source does not identify any meaningful cost leadership advantage. Raw materials are generally available from multiple sources, and while some single-supplier dependencies exist, no proprietary cost structure is indicated.

Overall, Stryker appears to possess a real structural moat in robotics and patent-protected innovation, while its growth trajectory is also reinforced by strong execution across a diversified medtech platform.

Outlook & Innovation Pipeline

The source does not provide explicit three-year guidance, but it does point to a clear strategic roadmap centered on innovation, portfolio expansion, and selective M&A.

Key forward-looking themes include:

• Robotics expansion: Continued development and commercialization of the Mako SmartRobotics platform, including advanced hip applications, revision procedures, and shoulder integration.
• Neurovascular and vascular innovation: Ongoing emphasis on products such as Surpass Elite Flow Diverting Stent and Surpass Evolve FDS, including international launches such as Japan.
• Product enhancement in instruments: Steri-Shield 8 reflects continued refinement of surgical instruments through improvements in visibility, cooling, and battery performance.
• Medical technology integration: The acquisition of Advanced Medical Balloons and the integration of care.ai with Vocera indicate a broader push into adjacent clinical workflows and AI-assisted virtual care.
• R&D intensity: The company reported more than $1.2 billion of year-to-date R&D spend in Q3 2025, underscoring a substantial commitment to innovation-led growth.
• Global expansion: With sales in approximately 75 countries, international growth remains an important strategic lever, particularly in vascular and neuro-related categories.

In sum, the next phase of Stryker’s development appears to be driven by a combination of platform expansion, product innovation, and disciplined acquisition activity, with robotics and neurotechnology standing out as the most strategically important vectors.